PATENT CLAIM ANALYSIS

Application Number: 16025315
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-12
Patent Classification: ["424", "450000"]

Abstract:
The present invention discloses an anti-tumor conjugate and pharmaceutical composition or kits comprising the conjugate, as well as a method of producing the anti-tumor conjugate. The anti-tumor conjugate of the present invention is metabolically stable in vivo, and is ultimately available for the treatment of tumors and production of anti-tumor medicaments.

Claim (Index 51):
A conjugate formed by coupling one polyethylene glycol molecule to one endostatin molecule, wherein the polyethylene glycol molecule is coupled to endostatin at the N-terminal \u03b1-amino group of endostatin and the polyethylene glycol has an average molecular weight from 20 kDa to 40 kDa, and wherein the conjugate has an enhanced biological activity compared to a native endostatin molecule.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 95.0
- Lexical Diversity: 1.61765
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['10358311', '12335361', '11089945', '12415142', '10232316']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6520109042710946
- 35 USC 102 Novelty (BERT): 0.498980191721842
- Combined Prediction Score: 0.6367078330161694
- Mean Citation Score: 230.735322
- Max Citation Score: 232.8836
- Similarity Product: 156.95393268010616

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test